Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
05/2000
05/31/2000EP1004593A2 Backbone modified oligonucleotide analogues
05/31/2000EP1004586A2 Method for producing 2-methylspiro(1,3-Oxathiolane-5,3')quinuclidine
05/31/2000EP1004583A2 Process and hydantoin intermediates for the synthesis of growth hormone secretagogues
05/31/2000EP1004582A2 Pyridazino quinoline compounds
05/31/2000EP1004581A2 Process for the preparation of thalidomide
05/31/2000EP1004580A2 Imides as inhibitors of TNF alpha
05/31/2000EP1004578A2 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
05/31/2000EP1004572A2 Amines as inhibitors of TNF alpha
05/31/2000EP1004320A1 Use of magnesium (Mg2+) for the enhancement of gene delivery in gene therapy
05/31/2000EP1004293A2 Targeted delivery via biodegradable polymers
05/31/2000EP1004022A1 Methods and compositions for overcoming resistance to biologic and chemotherapy
05/31/2000EP1003880A2 Human ubiquitin carrier protein e2-like protein and cyclin b-like protein
05/31/2000EP1003862A1 Human longevity-assurance protein homologs
05/31/2000EP1003861A2 Mammalian cell membrane proteins; related reagents
05/31/2000EP1003858A1 New human growth regulator protein
05/31/2000EP1003856A1 Apaf-1, the ced-4 human homolog, an activator of caspase-3
05/31/2000EP1003850A1 Inhibitors of dna immunostimulatory sequence activity
05/31/2000EP1003784A1 Novel peptides and polypeptides useful for regenerating the nervous system
05/31/2000EP1003781A1 Interleukin-18 binding proteins, their preparation and use
05/31/2000EP1003774A1 GnRH ANTAGONISTS BEING MODIFIED IN POSITIONS 5 AND 6
05/31/2000EP1003773A1 Ctl epitopes from ebv
05/31/2000EP1003772A1 Chemical modification of proteins to improve biocompatibility and bioactivity
05/31/2000EP1003770A1 Secreted proteins and polynucleotides encoding them
05/31/2000EP1003768A1 Secreted proteins and polynucleotides encoding them
05/31/2000EP1003767A1 Human tumor necrosis factor receptor tr10
05/31/2000EP1003748A2 Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase
05/31/2000EP1003745A1 Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
05/31/2000EP1003743A1 3,3-disubstituted piperidines as modulators of chemokine receptor activity
05/31/2000EP1003740A2 Pyrrolidine-3-carboxylic acid derivatives and their use as endothelin antagoists
05/31/2000EP1003739A2 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1h-indole derivatives
05/31/2000EP1003738A1 Bicyclic compounds as ligands for 5-ht1 receptors
05/31/2000EP1003729A1 6-azauracil derivatives as il-5 inhibitors
05/31/2000EP1003728A1 2- 3- 4-(2-t-butyl-6- trifluoromethylpyridin-4-yl) piperazin-1-yl] propylmercapto pyrimidin-4-ol-fumarate
05/31/2000EP1003721A1 Benzylidene-1,3-dihydro-indol-2-one derivatives as receptor tyrosine kinase inhibitors, particularly of raf kinases
05/31/2000EP1003712A1 Anthranilic acid analogs
05/31/2000EP1003706A1 Cyclohexenone long-chain alcohol and medicament containing same
05/31/2000EP1003546A1 Methods for treatment of patients afflicted wih multiple sclerosis using consensus interferon
05/31/2000EP1003545A1 Heparin-binding growth factor (hbgf) polypeptides
05/31/2000EP1003544A1 C1q AND COLLECTIN RECEPTOR
05/31/2000EP1003543A1 Apoptosis-inducing gelsolin sequences
05/31/2000EP1003541A1 Inhibitors of hiv reverse transcriptase
05/31/2000EP1003540A1 $g(b)2-ADRENERGIC RECEPTOR AGONISTS
05/31/2000EP1003532A1 Absorption of minerals by intestinal cells
05/31/2000EP1003530A1 Eye treatments using synthetic thyroid hormone compositions
05/31/2000EP1003528A1 Method of enhancing bioavailability of fexofenadine and its derivatives
05/31/2000EP1003526A1 Covalently linked n,o-carboxymethylchitosan and uses thereof
05/31/2000EP1003516A1 Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects
05/31/2000EP1003514A1 Cyclic amine modulators of chemokine receptor activity
05/31/2000EP1003512A1 ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS
05/31/2000EP1003511A1 ALPHA 1aADRENERGIC RECEPTOR ANTAGONISTS
05/31/2000EP1003509A1 Il-8 receptor antagonists
05/31/2000EP1003507A1 Combination therapy comprising amlodipine and a statin compound
05/31/2000EP1003504A2 Indole derivatives and their use as mcp-1 antagonists
05/31/2000EP1003503A1 Therapeutic combinations comprising amlodipin and atorvastatin
05/31/2000EP1003498A1 Di-aryl ethers and their derivatives as anti-cancer agents
05/31/2000EP1003497A1 Il-8 receptor antagonists
05/31/2000EP1003493A1 Use of selective rxr agonists to prevent surgical adhesions
05/31/2000EP1003492A2 Inhibitors of nf-kappab as activators of hsf and inducers of heat shock proteins
05/31/2000EP1003479A1 Method and compositions for treating late phase allergic reactions and inflammatory diseases
05/31/2000EP1003379A1 Novel phytase
05/31/2000EP1003374A4 Inhibitors of farnesyl-protein transferase
05/31/2000EP1003374A1 Inhibitors of farnesyl-protein transferase
05/31/2000EP1003373A1 Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
05/31/2000EP1003370A1 Method of enhancing magnesium absorption and prevention of atherosclerosis
05/31/2000EP0882016B1 Alkylated styrenes as prodrugs to cox-2 inhibitors
05/31/2000EP0828854B1 Analytical and therapeutic agents
05/31/2000EP0793495B1 Freeze-dried ondansetron compositions
05/31/2000EP0697011B1 Large potassium bicarbonate crystals and process for the preparation thereof
05/31/2000EP0688215B1 3,4-diarylchromans for treatment of dermatitis
05/31/2000EP0646005B1 Use of an imidazole for the preparation of a medicament for the treatment of arteriosclerosis
05/31/2000EP0631619B1 Reconstituted cartilage tissue
05/31/2000EP0627921B1 Method of inhibiting carcinogenesis by treatment with dehydroepiandrosterone and analogs thereof
05/31/2000DE19955794A1 Pyrrolidin-Derivate-CCR-3-Rezeptor-Antagonisten Pyrrolidine derivatives-CCR-3 receptor antagonists
05/31/2000DE19955340A1 CCR-3-Rezeptor-Antagonisten CCR-3 receptor antagonists
05/31/2000CN1255163A Compounds
05/31/2000CN1255162A Protease inhibitors
05/31/2000CN1255142A B-ring estratriene diol sulphates
05/31/2000CN1255141A Salts of 5 'alpha'-pregn-16-en-3 'beta'-ol-20-one 3-sulphate ester with progestin activity
05/31/2000CN1255136A Substituted 4-arylmethylene-2-imino-2,3-dihydrothiazoles and derivatives and their pharmaceutical use
05/31/2000CN1255135A New class of benzoporphyrin derivative photoactive compounds
05/31/2000CN1255131A Amidine derivatives as inhibitors of nitric oxide synthase
05/31/2000CN1255130A Compounds
05/31/2000CN1255119A Protease inhibitors
05/31/2000CN1255117A Excitatory amino acid receptor modulators
05/31/2000CN1255064A Use of 'alpha'-methyl-P-tyrosine to inhibit melanin production in iris melanocytes
05/31/2000CN1255062A Use of quinazoline compounds for the treatment of polycystic kidney disease
05/31/2000CN1255061A Use of chelerythrine and radiation for tumor therapy
05/31/2000CN1255059A COX-2 selective carprofen for treating pain and inflammation in dogs
05/31/2000CN1255056A Intravaginal drug delivery devices for idminsitration of testosterone and testosterone precursors
05/31/2000CN1255041A Methods and compositions for treatment of aids-associated kaposi's sarcoma
05/31/2000CN1254589A Medicine for treating Baisai's disease and its preparing process
05/31/2000CN1254576A Antistaling aloe tablet and its preparing process
05/31/2000CN1053012C Hog choera virus vaccine and diagnostic
05/31/2000CN1052978C Process for the preparation of alpha-tocopherol
05/31/2000CN1052976C Substituted benzenesulfonylureas and -thioureas, preparation process and possible uses of pharmaceutical preparation therefor
05/30/2000US6069230 High level expression and facile purification of proteins, peptides and conjugates for immunization, purification and detection applications
05/30/2000US6069175 Administering to a mammal in need a therapeutically effective amount of a member selected from the 4-hydroxy tamoxifen, raloxifene, toremifene, centchroman, idoxifene to treat atherosclerosis
05/30/2000US6069168 Compositions for treatment of diabetic complications
05/30/2000US6069156 Indole derivatives as cGMP-PDE inhibitors
05/30/2000US6069152 Nervous system disorders; cardiovascular disorders; gastrointestinal disorders
1 ... 1155 1156 1157 1158 1159 1160 1161 1162 1163 1164 1165 1166 1167 1168 1169 1170 1171 1172 1173 1174 1175 ... 1564